辅仁药业(600781)公告正文

辅仁药业:2014年半年度报告摘要

公告日期:2014-08-27

                            辅仁药业集团实业股份有限公司 2014 年半年度报告摘要
                            辅仁药业集团实业股份有限公司
                                   2014 年半年度报告摘要
    一、 重要提示
    1.1 本半年度报告摘要来自半年度报告全文,投资者欲了解详细内容,应当仔细阅读同时刊载于上海证券交易所网站等中国证监会指定网站上的半年度报告全文。
    1.2 公司简介
             股票简称                    辅仁药业                  股票代码                  600781
          股票上市交易所                                      上海证券交易所
         联系人和联系方式                    董事会秘书                           证券事务代表
               姓名                              张海杰                                 孙佩琳
               电话                         0371-60107778                         0371-60107778
               传真                         0371-60107755                         0371-60107755
             电子信箱                     zhanghj@shfuren.cn                  sunpeilin@eastday.com
    二、 主要财务数据和股东变化
    2.1 主要财务数据
                                                                                        单位:元 币种:人民币
                                                                                          本报告期末比上
                                             本报告期末               上年度末
                                                                                          年度末增减(%)
    总资产                                      1,099,315,973.33         907,128,232.04                   21.19
    归属于上市公司股东的净资产                    291,891,189.28         278,035,350.35                    4.98
                                                                                          本报告期比上年
                                                本报告期              上年同期
                                                                                            同期增减(%)
    经营活动产生的现金流量净额                      -9,169,120.46         22,894,938.02                 -140.05
    营业收入                                      195,077,734.86         183,188,990.78                    6.49
    归属于上市公司股东的净利润                      13,855,838.93         11,659,297.24                   18.84归属于上市公司股东的扣除非经常性
                                                10,239,666.22          8,226,902.91                   24.47损益的净利润
                                                                                           增加 0.45 个百分
    加权平均净资产收益率(%)                                  4.86                  4.41
                                                                                                         点
    基本每股收益(元/股)                                   0.0780               0.0657                  18.72
    稀释每股收益(元/股)                                   0.0780               0.0657                  18.72
    2.2    截止报告期末股东总数及持有公司 5%以上股份的前十名股东情况
                                                                                                      单位:股
    报告期末股东总数                                                                                      12,152
    截止报告期末表决权恢复的优先股股东总数(户)                                                                    0前 10 名股东持股情况
                                     持股比例                     持有有限售条件
    股东名称           股东性质                  持股数量                       质押或冻结的股份数量
                                       (%)                          的股份数量
    辅仁药业集团有限公 境 内 非 国 有 27.08          48,100,024                         质押         38,100,000
                             辅仁药业集团实业股份有限公司 2014 年半年度报告摘要
    司                   法人
    严春凤               境内自然人 1.19            2,121,714                        无
    郭丁黎               境内自然人 0.62            1,107,343                        无
    张德胜               境内自然人 0.62            1,106,953                        无
    魏哲慧               境内自然人 0.62            1,106,800                        无
    周后达               境内自然人 0.57            1,017,924                        无
    张卓                 境内自然人 0.55            983,601                          无长安基金-光大银行
                     境内非国有
    -长安群英 3 号分级            0.49             876,200                          无
                     法人资产管理计划
    吴品金               境内自然人 0.48            852,700                          无山水控股集团有限公 境 内 非 国 有
                                   0.48          843,702                          无
    司                 法人
    2.3    控股股东或实际控制人变更情况
    □适用 √不适用
    三、 管理层讨论与分析
    3.1    董事会关于公司报告期内经营情况的讨论与分析
    公司报告期内实现归属母公司净利润 1,385.58 万元。公司本期实现营业总收入为 19,507.77 万元,较上年同期 18,318.90 万元增加 1,188.87 万元,2014 年 6 月份期末资产总计 109,931.60 万元,其中流动资产合计 49,994.53 万元、长期股权投资合计 1,106.96 万元、固定资产合计 43,373.71 万元、在建工程合计 5,909.99 万元、无形及其他资产合计 4,804.44 万元;期末负债合计 74,777.60 万元,其中:流动负债合计 43,578.91 万元。财务数据较大变动分析:
    序号        项目            期末金额            期初金额             变动金额          变动比率
      1    货币资金       165,934,778.01         82,834,553.21         83,100,224.80        100.32
      2    应收票据           3,003,574.20        5,163,331.56          -2,159,757.36       -41.83
      3    预付账款          74,568,381.94       12,195,397.60         62,372,984.34        511.45
      4    在建工程          59,099,877.05       25,397,586.10         33,702,290.95        132.70
                        本期累计金额          上期累计金额
      5    销售费用          23,708,514.61       34,611,285.86         -10,902,771.25       -31.50
      6    财务费用          15,875,216.84       11,888,288.66          3,986,928.18         33.54注释:
    1、   货币资金:期末较期初增加 100.32%,主要原因是子公司辅仁堂银行借款到账所致。
    2、   应收票据:期末较期初减少 41.83%,主要原因是子公司辅仁堂应收票据到期回款所致。
    3、   预付账款:期末较期初增加 511.45%,主要原因是子公司辅仁堂预付货款及工程款项所致。
    4、   在建工程:期末较期初增加 132.70%,主要原因是子公司辅仁堂预付货款及工程款项所致。
    5、   销售费用:本期较上期减少 31.50%主要原因是子公司辅仁堂当期减少促费用所致。
    6、   财务费用:本期较上期增加 33.54%主要原因是子公司辅仁堂本期银行融资咨询费的增加所致。
    3.2     主营业务分析
    1、   财务报表相关科目变动分析表
                           辅仁药业集团实业股份有限公司 2014 年半年度报告摘要
                                                                                       单位:元 币种:人民币
                科目                            本期数              上年同期数           变动比例(%)
    营业收入                                       195,077,734.86       183,188,990.78                   6.49
    营业成本                                       121,450,372.15       105,870,197.61                 14.72
    销售费用                                        23,708,514.61        34,611,285.86                 -31.50
    管理费用                                        17,444,718.31        16,408,896.59                   6.31
    财务费用                                        15,875,216.84        11,888,288.66                 33.54
    经营活动产生的现金流量净额                      -9,169,120.46        22,894,938.02                -140.05
    投资活动产生的现金流量净额                     -82,904,309.86        -13,847,221.38               498.71
    筹资活动产生的现金流量净额                     143,173,655.12        -35,182,042.60               -506.95
    3.3     行业、产品或地区经营情况分析
    1、     主营业务分行业、分产品情况
                                                                                        单位:元 币种:人民币
                                       主营业务分行业情况
                                                                  营业收入      营业成本       毛利率比
                                                   毛利率
    分行业         营业收入         营业成本                         比上年增      比上年增       上年增减
                                                   (%)
                                                                    减(%)         减(%)          (%)
                                                                                                减少 4.44
    药业         195,013,133.15   121,398,690.75              37.74         6.50           14.67
                                                                                                个百分点
    贸易              64,601.71         51,671.40             20.02
                                       主营业务分产品情况
                                                                  营业收入     营业成本        毛利率比
                                                   毛利率
    分产品        营业收入         营业成本                          比上年增     比上年增        上年增减
                                                   (%)
                                                                    减(%)        减(%)           (%)
                                                                                                减少 4.51
    胶囊剂        32,664,546.05    20,624,174.52             36.86        -0.31             7.35
                                                                                                个百分点
                                                                                                减少 3.69
    片剂           5,422,290.82     4,276,507.33             21.13       -48.40           -45.87
                                                                                                个百分点
                                                                                               减少 14.46
    冲剂          76,768,149.11    55,230,957.76             28.05       -23.93            -4.80
                                                                                               个百分点
                                                                                                增加 0.86
    胶剂          71,040,958.71    32,753,682.96             53.89       116.48           112.52
                                                                                                个百分点
                                                                                                增加 4.24
    饮片            128,357.18        250,020.33             -94.78       12.92            10.52
                                                                                                个百分点
    滴眼(鼻、                                                                                     增加 32.64
                100,635.89         79,384.56             21.12       -23.46           -45.86
    耳)剂                                                                                         个百分点
                                                                                               增加 27.26
    混悬剂           76,064.13         52,510.07             30.97        35.17            -3.10
                                                                                               个百分点
                                                                                               增加 11.94
    糖浆剂          224,564.47         207,859.2              7.44       -91.67           -92.62
                                                                                               个百分点
    注射剂         3,268,863.43     3,261,270.77              0.23        16.72            82.26   减少 35.88
                                辅仁药业集团实业股份有限公司 2014 年半年度报告摘要
                                                                                              个百分点
                                                                                              增加 0.43
    丸剂            299,460.05             279,342.5               6.72     -4.04       -4.48
                                                                                              个百分点
    口服液          5,011,555.1         4,374,059.83            12.72
    贴剂                 7,688.21           8,920.92            -16.03
    贸易             64,601.71             51,671.40            20.02
    3.4   投资状况分析
    1、 对外股权投资总体分析
    (1) 持有金融企业股权情况
                                                                         报告期
                                       期末持                  报告期
    所持对   最初投资 期初持股                         期末账面             所有者      会计核    股份来
                                       股比例                  损益
    象名称   金额(元) 比例(%)                      价值(元)           权益变      算科目      源
                                       (%)                   (元)
                                                                         动(元)申银万
    国股份                                                                              长期股    募集申
          2,012,100                                 2,012,100
    有限公                                                                              权投资      购
    司
    合计    2,012,100         /              /        2,012,100                          /          /
    2、 非金融类公司委托理财及衍生品投资的情况
    (1) 委托理财情况
    本报告期公司无委托理财事项。
    (2) 委托贷款情况
    本报告期公司无委托贷款事项。
    3、主要子公司、参股公司分析
    我公司的主要控股子公司为河南辅仁堂制药有限公司,成立于 2004 年。注册地在河南鹿邑县玄武经济开发区,为中医药制造行业,辅仁堂现注册资本为 27,416 万元,本公司控股 86.32%。截止 2014 年 6月 30 日,该公司总资产 105,797.24 万元,净资产 43,233.55 万元,2014 年上半上度实现营业收入为 19,501.31万元,营业利润 1,777.60 万元,净利润 1,933.19 万元。
    辅仁堂主要生产品种有:齿痛消炎灵颗粒、小儿清热宁颗粒、参芪健胃颗粒、益心通脉颗粒、降脂通便胶囊、糖尿乐胶囊、阿胶、鹿角胶等,主要品种多为中药保护品种或全国独家生产品种,在市场上具有较强的竞争优势。
    辅仁堂成立以来,一直坚持走大生产能力和医药创新开发并举的发展之路,始终注重产品质量问题,坚持"当成本与质量发生矛盾时,成本让位于质量;当产量与质量发生矛盾时,产量让位于质量"的质量观。在产能上,通过最近数年的连续投入,公司提取车间生产能力和仓储能力已得到大幅度的提升,2014 第二季度始,公司胶剂生产车间进行 GMP 认证改造。
    4、非募集资金项目情况
    报告期内,公司无非募集资金投资项目。
    四、 利润分配或资本公积金转增预案
    (一) 报告期实施的利润分配方案的执行或调整情况
    根据本公司 2014 年 4 月 24 日召开的第五届董事会第十四次会议通过的《2013 年度利润分配预案》。2013 年末未分配利润为-15,026,917.25 元。上海辅仁实业(集团)股份有限公司母公司 2013 年度末未分
                         辅仁药业集团实业股份有限公司 2014 年半年度报告摘要配利润为:-209,664,202.52 元。本年度利润分配预案为:不分配现金红利,不送红股,不进行资本公积转增股本。
    独立董事意见:公司董事会认为,公司提出的 2013 年度利润分配预案是符合有关法律法规和《公司章程》的相关规定